TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23830534

Group type: EXPERIMENTAL
Intervention: Information regarding herpes zoster vaccination via electronic message (for personal health record users)
Number of subjects: 2589

Group type: EXPERIMENTAL
Intervention: Information regarding herpes zoster vaccination via US Postal Service (for nonpersonal health record users)
Number of subjects: 2589

Group type: COMPARATOR
Intervention: Standard of care (control group for both personal and nonpersonal health record users)
Number of subjects: 2589
Study: 22131602

Group type: EXPERIMENTAL
Intervention: Home-based evaluation and treatment of OSA
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lab-based evaluation and treatment of OSA
Number of subjects: 135
Study: 19523047

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study: 17726365

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1428
Study: 15203781

Group type: EXPERIMENTAL
Intervention: Contingent ALL (C‐ALL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Contingent LAST (C‐LAST)
Number of subjects: 40
Study: 11380324

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Octreotide (125 microg)
Number of subjects: 33
Study: 9564987

Group type: EXPERIMENTAL
Intervention: Salbutamol/nedocromil combination (200 microg/4 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol alone (200 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 12
Study: 7981487

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iproplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JM216
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Tetraplatin
Number of subjects: 0
Study: 30265816

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) 100 µg/62.5 µg/25 µg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Budesonide/Formoterol (BUD/FOR) 400 µg/12 µg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Budesonide/Formoterol (BUD/FOR)
Number of subjects: 61
Study: 27424935

Group type: EXPERIMENTAL
Intervention: Sevelamer or calcium acetate, calcitriol, and changes in calcium dialysate concentration
Number of subjects: 52

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 52
Study: 24841018

Group type: EXPERIMENTAL
Intervention: Single dose of pre-operative antibiotics
Number of subjects: 251

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 251
Study: 23797006

Group type: COMPARATOR
Intervention: 20 mg chitosan gum twice daily for 4 weeks in ESRD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg chitosan gum three times daily in open-label extension in ESRD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg chitosan gum three times daily for 2 weeks in CKD not on dialysis
Number of subjects: 0
Study: 20207251

Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with povidone iodine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (no vaginal wash)
Number of subjects: 300
Study: 19249433

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with the Export catheter (n = 20)
Number of subjects: 44

Group type: COMPARATOR
Intervention: PCI-only group (n = 24)
Number of subjects: 44
Study: 16765187

Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: High-ligation surgery
Number of subjects: 56
Study: 14992738

Group type: EXPERIMENTAL
Intervention: Hemoglobin raffimer (HR)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 10% pentastarch
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard clinical practice (reference group)
Number of subjects: 299
Study: 11726473

Group type: COMPARATOR
Intervention: Tug of war athletes
Number of subjects: 16
Study: 9000193

Group type: EXPERIMENTAL
Intervention: Standard-dose polyagent self‐administered intracavernous pharmacotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: High-dose polyagent self‐administered intracavernous pharmacotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Vacuum constriction device (VCD)
Number of subjects: 188
Study: 7956623

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control subjects with apoA-IV-1-2 phenotype
Number of subjects: 83
Study: 3583493

Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) 25 nmol/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29133566

Group type: EXPERIMENTAL
Intervention: 80 mg iclaprim administered as a 2-h infusion every 12 h
Number of subjects: 470

Group type: COMPARATOR
Intervention: 0.8 mg/kg iclaprim infused intravenously over 0.5 h every 12 h (previous regimen)
Number of subjects: 470
Study: 27154868

Group type: EXPERIMENTAL
Intervention: Suprapatellar approach group (SPAG)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Infrapatellar approach group (IPAG)
Number of subjects: 162
Study: 24080948

Group type: EXPERIMENTAL
Intervention: Automatic test battery (including automatic pure-tone air conduction audiometry and tone-in-noise detection task)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Automatic tests (manual pure-tone air conduction audiometry and bone conduction audiometry)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Automatic test battery
Number of subjects: 120
Study: 23149085

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G‐GR) 1800mg
Number of subjects: 721

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study: 20494655

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of abciximab (0.25 mg/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intravenous delivery of abciximab (0.25 mg/kg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High-dose abciximab (>=0.30 mg/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard-dose abciximab (0.25 mg/kg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of abciximab
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High-dose abciximab
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clinical, angiographic and cardiac magnetic resonance imaging outcomes at 6 and 12 months
Number of subjects: 105
Study: 18632765

Group type: EXPERIMENTAL
Intervention: Bifocal right ventricular pacing (apical and outflow tract)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple site pacing (right ventricular apex, outflow tract, and lateral left ventricular pacing)
Number of subjects: 0
Study: 15689724

Group type: EXPERIMENTAL
Intervention: Skills-based treatment protocol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Supportive relationship therapy
Number of subjects: 39
Study: 14520034

Group type: EXPERIMENTAL
Intervention: Chronic whiplash‐associated disorders group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chronic insidious onset neck pain group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: C3-C4 segment in whiplash‐associated disorders group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: C5-C6 segment in whiplash‐associated disorders group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: C3-C4 segment in insidious onset neck pain group
Number of subjects: 34
Study: 10098817

Group type: EXPERIMENTAL
Intervention: Head Mounted Displays (HMDs)
Number of subjects: 0
Study: 8679346

Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 66% nitrous oxide in oxygen
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3% halothane in 66% nitrous oxide in oxygen
Number of subjects: 120
Study: 2052467

Group type: COMPARATOR
Intervention: Enalapril 10 mg daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily plus hydrochlorothiazide 25 mg daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Enalapril monotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 25
Study: 6137785

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Triazolam (0.5 mg)
Number of subjects: 94
Study: 30975106

Group type: EXPERIMENTAL
Intervention: Intervention group (high intervention dose)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Intervention group (boys beyond the 95th percentile)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Intervention group (overall)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Intervention group (girls)
Number of subjects: 215
Study: 27743846

Group type: EXPERIMENTAL
Intervention: Vocal Loading Task (VLT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Work
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leisure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (voice healthy)
Number of subjects: 50
Study: 25293966

Group type: EXPERIMENTAL
Intervention: Metacognitive detached mindfulness therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 45
Study: 25058771

Group type: EXPERIMENTAL
Intervention: ULTRAPRO Hernia System (UHS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lichtenstein technique (group L)
Number of subjects: 99
Study: 21681817

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19848201

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 17464731

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 30
Study: 15665959

Group type: EXPERIMENTAL
Intervention: Refracterin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 0
Study: 11164404

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (nailed group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Plaster cast (casted group)
Number of subjects: 27
Study: 9129897

Group type: EXPERIMENTAL
Intervention: Intravenous digoxin (mean dose 0.88 ± 0.35 mg)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo (mean dose 0.96 ± 0.37 mg)
Number of subjects: 239
Study: 8186114

Group type: EXPERIMENTAL
Intervention: Calcipotriol solution (50 micrograms/ml), applied twice daily for 4 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (vehicle solution), applied twice daily for 4 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Calcipotriol solution
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Calcipotriol solution and Placebo
Number of subjects: 49
Study: 2451930

Group type: EXPERIMENTAL
Intervention: Substance P (SP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neurokinin A (NKA)
Number of subjects: 6
Study: 30779061

Group type: EXPERIMENTAL
Intervention: Antibacterial-coated sutures (CHX-coated)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Uncoated sutures (Control)
Number of subjects: 36
Study: 29261242

Group type: EXPERIMENTAL
Intervention: ED-based care coordination intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 72
Study: 26687552

Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 15
Study: 25291974

Group type: EXPERIMENTAL
Intervention: sifuvirtide 10 mg q.d. for 28 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sifuvirtide 20 mg q.d. for 28 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sifuvirtide 20 mg q.d. in combination with HAART for 168 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: sifuvirtide (both doses)
Number of subjects: 27
Study: 21902704

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Novafen (325 mg paracetamol, 200 mg ibuprofen, 40 mg caffeine anhydrous)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18814935

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg with metoclopramide 10 mg
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo with metoclopramide 10 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg with metoclopramide 20 mg
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo with metoclopramide 20 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 286
Study: 17437152

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg/kg in 100 ml of saline, followed by 8 mg/kg/h infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (equal volume before induction and 8 mg/kg/h infusion)
Number of subjects: 60
Study: 15542186

Group type: EXPERIMENTAL
Intervention: StaphVAX
Number of subjects: 100
Study: 11435842

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 76
Study: 9777792

Group type: EXPERIMENTAL
Intervention: Tazarotene plus medium- or high-potency corticosteroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tazarotene plus placebo cream
Number of subjects: 0
Study: 7625470

Group type: EXPERIMENTAL
Intervention: Bright white light (600-lux)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dim red light (30-lux)
Number of subjects: 57
Study: 2199132

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0
Study: 900433

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propanidid (7 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Etomidate with faster injection rate (15 seconds)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Etomidate without atropine premedication
Number of subjects: 200
Study: 31964172

Group type: EXPERIMENTAL
Intervention: Case manager-assisted rehabilitation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no case manager-assisted rehabilitation)
Number of subjects: 82
Study: 31631093

Group type: EXPERIMENTAL
Intervention: Clinical pathway (CP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No clinical pathway
Number of subjects: 62
Study: 27837201

Group type: EXPERIMENTAL
Intervention: 0.2% sirolimus gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.1% sirolimus gel (adults)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.05% sirolimus gel (adults)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25951755

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 24267640

Group type: EXPERIMENTAL
Intervention: EndoFlex tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard endotracheal tube with intubation stylet
Number of subjects: 60
Study: 22017672

Group type: EXPERIMENTAL
Intervention: Combined relaxation (applied tension release, ATR) and specific shooting training for 10 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no special training intervention)
Number of subjects: 12
Study: 19554676

Group type: EXPERIMENTAL
Intervention: Threpsology support
Number of subjects: 0
Study: 17724727

Group type: EXPERIMENTAL
Intervention: seminal vesical‐prostatic base blockade
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: intraprostatic blockade
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: apical‐rectal blockade
Number of subjects: 243
Study: 15121563

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Desogestrel pills
Number of subjects: 191

Group type: COMPARATOR
Intervention: Nonhormonal contraception (control)
Number of subjects: 191
Study: 11273796

Group type: EXPERIMENTAL
Intervention: Ciclesonide (400 microg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Budesonide (400 microg)
Number of subjects: 15
Study: 9509441

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 26
Study: 8138836

Group type: EXPERIMENTAL
Intervention: Test-treated group (most severely ill)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-treated group (least severely ill)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomly assigned group (moderately ill)
Number of subjects: 0
Study: 2259898

Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 40

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 40
Study: 913230

Group type: EXPERIMENTAL
Intervention: Butaclamol (BT) 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Butaclamol (BT) 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Butaclamol (BT) 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31833394

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib/dexamethasone
Number of subjects: 302

Group type: COMPARATOR
Intervention: Carfilzomib/dexamethasone
Number of subjects: 302
Study: 30734717

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid at a daily dose of 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid at a daily dose of 750 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid at a daily dose of 1,000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid at a daily dose of 1,500 mg
Number of subjects: 0
Study: 28490529

Group type: EXPERIMENTAL
Intervention: 0.58 μmol NaNO2·kg‐1·h‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.74 μmol NaNO2·kg‐1·h‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.48 μmol NaNO2·kg‐1·h‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 12
Study: 24921623

Group type: EXPERIMENTAL
Intervention: Spinach supplementation (1 g/kg body weight daily for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spinach supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23505168

Group type: COMPARATOR
Intervention: Mediterranean Diet without weight loss (MedDiet - WL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mediterranean Diet with weight loss (MedDiet + WL)
Number of subjects: 26
Study: 16971664

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Treosulfan (GeT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treosulfan alone (T)
Number of subjects: 48
Study: 12559179

Group type: EXPERIMENTAL
Intervention: Standard pancreaticoduodenectomy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Radical pancreaticoduodenectomy
Number of subjects: 299
Study: 10562261

Group type: EXPERIMENTAL
Intervention: Early dipyridamole (99m)Tc-sestamibi MPI study
Number of subjects: 451

Group type: COMPARATOR
Intervention: Submaximal exercise (99m)Tc-sestamibi MPI study
Number of subjects: 451
Study: 8724947

Group type: EXPERIMENTAL
Intervention: Computer-based interactive methods (including touchscreen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original paper-and-pencil format
Number of subjects: 0
Study: 1996571

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 100 U/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6662170

Group type: EXPERIMENTAL
Intervention: 160 mg of long acting (L.A.) propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 200 mg of sustained action (S.A.) metoprolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 15
Study: 31705620

Group type: EXPERIMENTAL
Intervention: Active Involvement of Users in Research Observation Schedule and Questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31318033

Group type: EXPERIMENTAL
Intervention: Western diet high-fat meal plus postprandial walking (WD-W)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Western diet high-fat meal plus postprandial resting (WD-R)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet meal plus postprandial walking (MD-W)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mediterranean-type diet meal plus postprandial resting (MD-R)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet meal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Postprandial walking
Number of subjects: 26
Study: 28240186

Group type: EXPERIMENTAL
Intervention: Tender coconut water (TCW) 300 ml twice daily for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Water 300 ml twice daily for 14 days
Number of subjects: 32
Study: 24524383

Group type: EXPERIMENTAL
Intervention: Plant-based nutrition program (vegan diet) for 18 weeks
Number of subjects: 292
Study: 22981898

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR) - sustained 25% calorie restriction
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 21593117

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 27
Study: 19879499

Group type: EXPERIMENTAL
Intervention: Increased frequency of self-weighing
Number of subjects: 63

Group type: COMPARATOR
Intervention: Maintained or decreased frequency of self-weighing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Self-weighing frequency
Number of subjects: 63
Study: 16813179

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with consciousness‐restoring resuscitation method (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with traditional acupuncture (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional acupuncture (Group C)
Number of subjects: 120